Key Patent Expiries to Lead Global Anti-Hypertensive Market

Multiple major drug patent expiries will cause the global anti-hypertensive market value to decline from $40 billion in 2013 to $37.6 billion by 2020, at a negative Compound Annual Growth Rate (CAGR) of 0.9%, says business intelligence provider GBI Research.
The company’s latest report, Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries, states that while the anti-hypertensive market value is first expected to increase to $44.5 billion by 2017, representing a CAGR of 2.6%, it will then fall at a negative CAGR of 5.4% through to 2020.

“The initial expansion of this market will result from the increased penetration of fixed-dose combination drugs, such as Amturnide, Exforge, Tribenzor, Azor, Tekamlo, and Valturna. A rise in the prevalence of hypertension, from a population of 181 million to 190 million, combined with the anticipated launches of azilsartan + amlodipine and AHU377 + valsartan, will also contribute,” said Arti Singh, Analyst for GBI Research.

However, the hypertension market growth will be countered by significant drug patent expirations both prior to and during the forecast period, including those of Cozaar in 2010, Diovan, Avapro, and Atacand in 2012, Exforge in 2014, Benicar in 2016, and Tekturna and Tekturna HCT in 2018. A low diagnosis rate, teamed with a rise in generic penetration, will also drive the decline.

“Most of the drugs in the anti-hypertensives pipeline are generics, accounting for 77% of over 544 active molecules in development, while only 20% are novel drug candidates, added Mr. Singh. “The substantial number of active drug candidates, spread across the various stages of clinical development, demonstrates a strong overall pipeline. However, the novel approach is currently limited to a few targets, most notably non-dihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024).”

According to GBI Research, an increased uptake in combination therapies for treating hypertension will enable the anti-hypertensive market to survive despite the series of patent expiries. Furthermore, the report states that an expected rise in the prescription of renin inhibitors (Tekturna/Rasilez) over the forecast period will also keep the market growth steady.

Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries analyzes treatment usage patterns, market characterization, pipeline analysis, and key licensing and co-development deals in hypertension in the major developed markets. It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts. For more information, visit www.gbiresearch.com.